C12N 2830/36
Being a transcription termination element
Official title: being a transcription termination element
C12N2830/36 (Being a transcription termination element) appears on 47 US grants and 67 published applications in this corpus.
Search patents in C12N- Granted patents
- 47
- Published applications
- 67
- Assignees
- 56
- Inventors
- 202
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 4 | 0 |
| 1998 | 3 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 2 |
| 2003 | 3 | 1 |
| 2004 | 0 | 0 |
| 2005 | 3 | 2 |
| 2006 | 0 | 0 |
| 2007 | 2 | 0 |
| 2008 | 1 | 3 |
| 2009 | 0 | 1 |
| 2010 | 0 | 3 |
| 2011 | 2 | 2 |
| 2012 | 1 | 2 |
| 2013 | 0 | 1 |
| 2014 | 2 | 0 |
| 2015 | 1 | 2 |
| 2016 | 2 | 2 |
| 2017 | 0 | 1 |
| 2018 | 1 | 3 |
| 2019 | 1 | 1 |
| 2020 | 0 | 4 |
| 2021 | 1 | 8 |
| 2022 | 1 | 6 |
| 2023 | 2 | 3 |
| 2024 | 1 | 5 |
| 2025 | 5 | 3 |
| 2026 | 2 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- AAV delivery of nucleobase editors30 Jun 2026US 12,668,815 B2President and Fellows of Harvard College
- Multivalent HVT vector vaccine31 Mar 2026US 12,589,147 B2Intervet Inc.
- Inducible promoters26 Aug 2025US 12,398,397 B2Worcester Polytechnic Institute
- Multifunctional nucleic acid reporter constructs29 Jul 2025US 12,371,709 B2Dana-Farber Cancer Institute, Inc.
- Systems and methods for modulating chromosomal rearrangements15 Jul 2025US 12,359,223 B2Editas Medicine, Inc.
- Genetically modified yeast and fermentation processes for the production of ethanol1 Oct 2026US 2026/0297503 A1Cargill, Incorporated
- Production of a negatively charged oligosaccharide by a cell24 Sep 2026US 2026/0286409 A1Inbiose N.V.
- Circular single-stranded dna molecules for recombinase-based gene editing17 Sep 2026US 2026/0275344 A1Fc IP Holdings, LLC
- Coumarin synthesis and uses thereof17 Sep 2026US 2026/0275368 A1BASF SE
- Expression cassette combination and use thereof3 Sep 2026US 2026/0258112 A1
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998